Bristol-Myers Squibb (BMY) has been at the center of several monumental updates. Owing to the strength of their cardiovascular portfolio and successful Q3 earnings call, BMY stock impresses with a 5.7% rise over last week. Following their CAR-T cell therapy Breyanzi's approval and a positive CHMP opinion for Opdivo® and Yervoy®'s first-line treatment, there has been significant growth. AbbVie's failed schizophrenia-drug trial also led to a soar in Bristol Myers’s stock. Despite being subjected to a $6.7 billion lawsuit over delayed cancer drug, the biotech firm fights back, showcasing its financial resilience. They have seen an upgrade to \"Strong-Buy\" from Daiwa and Leerink, with Citigroup raising the price target to $60. Acquisitions have contributed to growth, as has the approval for their novel schizophrenia drug. Amidst strategic purchases and increased stakes by major financial institutions, BMY's high institutional ownership showcases investors' confidence in the company. With the BMY stock currently trending, the future looks promising due to strong demand for their new drugs, contributing to a boosted 2024 outlook.
Bristol-Myers Squibb BMY News Analytics from Thu, 14 Mar 2024 07:00:00 GMT to Sat, 16 Nov 2024 14:37:14 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor 4
